Clinical Trial Update: Respiratory Syncytial Virus (RSV) Investigational Vaccine in Infants Aged 6 and 7 Months Likely to be Unexposed to RSV [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial update for an RSV investigational vaccine in infants 6–7 months old completed; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infections

Drugs mentioned

• GlaxoSmithKline RSV investigational vaccine

Snippet

Sponsor: GlaxoSmithKline | Conditions: Respiratory Syncytial Virus Infections | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-07-27